OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA Mutation Carriers

A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers.  These models, which target the cell of origin (fallopian tube secretory cells) and recreate key genetic alterations and precursor lesions characteristic of the human disease, will allow the development of better early detection and prevention strategies for women at increased risk.

This research, funded in part by OCRF, was co-led by current OCRF grantee Daniela Dinulescu, PhD and former grantee and OCRF Scientific Advisory Committee member Ronny Drapkin, MD, PhDRuth Perets, MD, PhD, also an OCRF grantee, was the first author of the paper, which was published in Cancer Cell this week.

Click here to read the abstract of this article.